Another example is that there are numerous drugs targeting SREBF1, many of which are utilized in lipid lowering, treating NAFLD or in tumor research (Cai et al. 2023), as well as being newly discovered targets of some traditional drugs (Deng et al. 2021), etc. And through the analysis results of this study, it is obvious that the tissue-specific expression of SREBF1 varies significantly, and even in different phases of the progression of T2D and NAFLD, the expression and mechanism of action are dissimilar. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.